Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Common side effects are gastrointestinal (nausea, reduced appetite)
Those who continued on the drug lost more weight (an additional 5.5% on average), while those on the placebo regained 14% of the weight they had lost
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity
BPI Labs claims to be the only FDA-registered drug manufacturer with a 503B pharmacy producing GLP-1 medications using this level of automation
For someone weighing 90 kg, this amounts to around 110-145 grams of protein daily, or a serving the size of the palm of your hand in each meal
